These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28739264)

  • 1. Preface - Matrix metalloproteinases.
    Fridman R
    Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt A):1925-1926. PubMed ID: 28739264
    [No Abstract]   [Full Text] [Related]  

  • 2. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects.
    Levin M; Udi Y; Solomonov I; Sagi I
    Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt A):1927-1939. PubMed ID: 28636874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural studies of matrix metalloproteinases.
    Borkakoti N
    J Mol Med (Berl); 2000; 78(5):261-8. PubMed ID: 10954198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress in the development of matrix metalloproteinase inhibitors.
    Tu G; Xu W; Huang H; Li S
    Curr Med Chem; 2008; 15(14):1388-95. PubMed ID: 18537616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of self-immolative linkers in the design of hydrogen peroxide activated metalloprotein inhibitors.
    Jourden JL; Daniel KB; Cohen SM
    Chem Commun (Camb); 2011 Jul; 47(28):7968-70. PubMed ID: 21677985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.
    Zhang YM; Fan X; Xiang B; Chakravarty D; Scannevin R; Burke S; Karnachi P; Rhodes K; Jackson P
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3096-100. PubMed ID: 16632358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzymatic activation of a matrix metalloproteinase inhibitor.
    Major Jourden JL; Cohen SM
    Chem Commun (Camb); 2010 Feb; 46(8):1241-3. PubMed ID: 20449263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinase inhibitors: specificity of binding and structure-activity relationships.
    Gupta SP
    Exp Suppl; 2012; 103():v-vi. PubMed ID: 22642187
    [No Abstract]   [Full Text] [Related]  

  • 9. Analysis of matrix degradation.
    Munshi HG; Stack MS
    Methods Cell Biol; 2002; 69():195-205. PubMed ID: 12070993
    [No Abstract]   [Full Text] [Related]  

  • 10. [Matrix metalloproteinases, their inhibitors and angiogenesis in different morphological types of lung precancer in persons who have long lived in the radioactive substance-polluted area of the Semipalatinsk Region, Kazakhstan].
    Sagindikova GE; Kogan EA; Satbaeva EB; Paramonova NB
    Arkh Patol; 2008; 70(2):21-5. PubMed ID: 18540436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloprotease inhibitors: design from structure.
    Borkakoti N
    Biochem Soc Trans; 2004 Feb; 32(Pt 1):17-20. PubMed ID: 14748704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinases.
    Fridman R
    Biochim Biophys Acta; 2010 Jan; 1803(1):1-2. PubMed ID: 20159302
    [No Abstract]   [Full Text] [Related]  

  • 13. Conference report--extracellular matrix and cancer: revisiting metalloproteinases highlights from the annual meeting of the American Society for Cell Biology; December 13-17, 2003; San Francisco, California.
    Mariani SM
    MedGenMed; 2004 Feb; 6(1):25. PubMed ID: 15208537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors.
    Skiles JW; Gonnella NC; Jeng AY
    Curr Med Chem; 2001 Mar; 8(4):425-74. PubMed ID: 11172697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico study of MMP inhibition.
    Rouffet M; Denhez C; Bourguet E; Bohr F; Guillaume D
    Org Biomol Chem; 2009 Sep; 7(18):3817-25. PubMed ID: 19707688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Snapshots of the reaction mechanism of matrix metalloproteinases.
    Bertini I; Calderone V; Fragai M; Luchinat C; Maletta M; Yeo KJ
    Angew Chem Int Ed Engl; 2006 Dec; 45(47):7952-5. PubMed ID: 17096442
    [No Abstract]   [Full Text] [Related]  

  • 17. A comparative docking study and the design of potentially selective MMP inhibitors.
    Hanessian S; Moitessier N; Therrien E
    J Comput Aided Mol Des; 2001 Oct; 15(10):873-81. PubMed ID: 11918074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative structure-activity relationship studies on zinc-containing metalloproteinase inhibitors.
    Gupta SP
    Chem Rev; 2007 Jul; 107(7):3042-87. PubMed ID: 17622180
    [No Abstract]   [Full Text] [Related]  

  • 19. Matrix metalloproteinases (MMPs) in health and disease: an overview.
    Malemud CJ
    Front Biosci; 2006 May; 11():1696-701. PubMed ID: 16368548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intra- and interdomain flexibility in matrix metalloproteinases: functional aspects and drug design.
    Bertini I; Fragai M; Luchinat C
    Curr Pharm Des; 2009; 15(31):3592-605. PubMed ID: 19925414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.